Cardiovascular complications during the treatment of castration-resistant prostate cancer with the use of modern antiandrogens: abiraterone acetate and enzalutamide Review article

Main Article Content

Radosław Grabysa
Agnieszka Chmielewska


Modern antiandrogens: abiraterone acetate (inhibitor of CYP17 cytochrome) and enzalutamide (irreversible inhibitor of androgen receptor) are the drugs that are increasingly often administered in treatment of castration-resistant prostate cancer. Despite their clinical efficacy, especially in terms of prolonged survival and improved quality of life of patients, they pose of problem for a practicing oncologist such as possible cardiovascular complications (particularly arterial hypertension), which may lead to the cessation of this form of therapy. This article provides a brief overview of the mechanisms responsible for the above complications, including practical recommendations in the event such complications arise. A simple scheme of action for control of cardiovascular risk factors has been presented, which can improve the prognosis in this population of patients.


Download data is not yet available.


Metrics Loading ...

Article Details

How to Cite
Grabysa R, Chmielewska A. Cardiovascular complications during the treatment of castration-resistant prostate cancer with the use of modern antiandrogens: abiraterone acetate and enzalutamide. OncoReview [Internet]. 2021Sep.13 [cited 2022May16];11(3(43):61-7. Available from:


1. Krajowy Rejestr Nowotworów (access: 12.07.2021).
2. Epstein MM, Edgren G, Rider JR et al. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst. 2012; 104: 1335-42.
3. Nguyen PL, Alibhai SMH, Basaria S et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015; 67(5): 825-36.
4. Tzortzis V, Samarinas M, Zachos I et al. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Hormones (Athens). 2017; 16: 115-23.
5. Gupta D, Lee Chuy K, Yang JC et al. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate. Cancer Oncol Pract. 2018; 14(10): 580-7.
6. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24: 4448-56.
7. Guo Z, Huang Y, Gong L et al. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018; 21: 451-60.
8. Rehman Y, Roseberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther. 2012; 6: 13-8.
9. Charakterystyka produktu leczniczego Zytiga® (access: 12.07.2021).
10. Fizazi K, Tran N, Fein L et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017; 377: 352-60.
11. Zhu X, Wu S. Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis. Clin Hypertens. 2019; 25: 5.
12. vanDorst DCH, Dobbin SJH, Neves KB et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circ Res. 2021; 128: 1040-61.
13. Xtandi – charakterystyka produktu leczniczego (access: 12.07.2021).
14. Schalken J, Fitzpatrick JM. Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer. BJU Int. 2016; 117(2): 215-25.
15. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367: 1187-97.
16. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371: 424-33.
17. Hussain M, Fizazi K, Saad F et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018; 378: 2465-74.
18. Salem JE, Yang T, Moslehi JJ et al. Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation. 2019; 140: 1070-80. AHA.119.040162.
19. Attard G, Reid AH, Auchus RJ et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab. 2012; 97(2): 507-16.
20. Kosicka K, Główka FK, Kośla A et al. Rola glikokortykosteroidów w etiologii nadciśnienia tętniczego. Nadciśnienie Tętnicze. 2010; 14(3): 208-15.
21. Bhatia N, Santos M, Jones LW et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer. Circulation. 2016; 133; 5: 537-41.
22. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39: 3021-104.
23. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5: 1-86.
24. Mc Menamin UC, Murray LJ, Cantwell MM et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 2012; 23: 221-30.
25. Gill D, Gaston D, Bailey E et al. Efficacy of eplerenone in the management of mineralocorticoid excess in men with metastatic castration-resistant prostate cancer treated with abiraterone without prednisone. Clin Genitourin Cancer. 2017; 15(4): e599-602.
26. Dhondt B, Buelens S, Van Besien J et al. Abiraterone and spironolactone in prostate cancer: a combination to avoid. Acta Clin Belg. 2019; 74(6): 439-44.